Resource Summary Report

Generated by NIF on Sep 9, 2026

NCI-H2170

RRID:CVCL_1535
Type: Cell Line

Proper Citation

RRID:CVCL_1535

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1535

Proper Citation: RRID:CVCL_1535

Description: Cell line NCI-H2170 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung squamous cell carcinoma

Defining Citation: PMID:8806092, PMID:11030152, PMID:16187286, PMID:18083107, PMID:20164919, PMID:20215515, PMID:22460905, PMID:22961666, PMID:24002593, PMID:25485619, PMID:25877200, PMID:26589293, PMID:27397505, PMID:28196595, PMID:29681454, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31395879, PMID:31803961, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: EGFR genetic alteration cell panel (ATCC TCP-1027)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H2170

Synonyms: H2170, H-2170, NCIH2170

Cross References: BTO:BTO_0005425, CLO:CLO_0008059, EFO:EFO_0002281, AddexBio:C0016018/4970, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5928, BCRJ:0271, BioGRID_ORCS_Cell_line:529,

BioSample:SAMN03471883, BioSample:SAMN10988373, cancercelllines:CVCL_1535, CCRID:1101HUM-PUMC000354, Cell_Model_Passport:SIDM00716, ChEMBL-Cells:CHEMBL3308460, ChEMBL-Targets:CHEMBL1075534, CLS:305276, Cosmic:687815, Cosmic:1802304, Cosmic:1995561, Cosmic:2042870, Cosmic:2060537, Cosmic:2125196, Cosmic:2664252, Cosmic-CLP:687815, DepMap:ACH-000481, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:687815, GEO:GSM62966, GEO:GSM434789, GEO:GSM784214, GEO:GSM794356, GEO:GSM827511, GEO:GSM844639, GEO:GSM887410, GEO:GSM888489, GEO:GSM1670221, IARC_TP53:21558, IGRhCellID:NCIH2170, LiGeA:CCLE_581, LINCS_LDP:LCL-1590, Lonza:949, PharmacoDB:NCIH2170_1074_2019, PRIDE:PXD030304, Progenetix:CVCL_1535, PubChem_Cell_line:CVCL_1535, Wikidata:Q54907934

ID: CVCL_1535

Record Creation Time: 20220427T220839+0000

Record Last Update: 20260905T181243+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H2170.

No alerts have been found for NCI-H2170.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Ishida M, et al. (2026) AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers. NPJ precision oncology, 10(1).

Chuikov S, et al. (2026) E2A selectively regulates TGF-??-induced apoptosis in KRAS-mutant non-small cell lung cancer. Molecular oncology, 20(7), 1877.

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer discovery, 16(1), 81.

Brunner JS, et al. (2026) Aspartate availability drives differential engagement of the malate-aspartate shuttle. Molecular cell, 86(5), 954.

Brady MR, et al. (2026) Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma. Cancer research, 86(5), 1166.

Nilsson MB, et al. (2026) Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 21(6), 103555.

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. Cell reports. Medicine, 7(4), 102694.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Cancer cell, 43(8), 1530.

Wang X, et al. (2025) HACD3 promotes malignant progression of NSCLC by suppressing the MKK7/MAPK10 signaling axis. BMC cancer, 25(1), 1317.

Park J, et al. (2025) MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer. Cell reports, 44(6), 115722.

Morel M, et al. (2024) FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling. Molecular oncology, 18(3), 762.

Suvilesh KN, et al. (2024) Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non-Small Cell Lung Cancer Patient-Derived Tumor Organoids. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(17), 3855.

Savage SR, et al. (2024) Pan-cancer proteogenomics expands the landscape of therapeutic targets. Cell, 187(16), 4389.

Kong C, et al. (2023) MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors. Molecular cancer therapeutics, 22(10), 1128.

Guo L, et al. (2023) Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors. iScience, 26(8), 107302.

Zhang S, et al. (2020) The Negative Cross-Talk between SAG/RBX2/ROC2 and APC/C E3 Ligases in Regulation of Cell Cycle Progression and Drug Resistance. Cell reports, 32(10), 108102.

Liu Y, et al. (2020) Chromosome 3q26 Gain Is an Early Event Driving Coordinated Overexpression of the PRKCI, SOX2, and ECT2 Oncogenes in Lung Squamous Cell Carcinoma. Cell reports, 30(3), 771.

Ge P, et al. (2019) miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer. BMC cancer, 19(1), 1203.

Zhou W, et al. (2018) UBE2M Is a Stress-Inducible Dual E2 for Neddylation and Ubiquitylation that Promotes Targeted Degradation of UBE2F. Molecular cell, 70(6), 1008.

Momcilovic M, et al. (2018) The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. Cancer cell, 33(5), 905.